This week I’ve got a little teaser decipherization for you to get us started, and we’ve also got a new piece from Dr. KSS… and I’ve got some updated thoughts on a few other stocks at the end of today’s piece. The teaser? Well, it’s been circulating for a few weeks now, and it caught […]
Nikola Tesla has probably gotten more attention in the last five years than at any other time since he passed away during World War 2… for a while it was enough that the car company named after him was a daily headline generator and stock market darling, but now he’s also being connected to work […]
Another biotech teaser for you today — these never seem to stop, perhaps partly because small biotech stocks are almost the only ones, other than little junior miners, that have a legitimate chance of seeing their prospects change dramatically overnight or see rapid 100%, 200%, 500% share price gains on a new discovery or shockingly […]
Who can resist that headline, right? If for no other reason than you want to check and see if maybe you own that “next major U.S. stock” that former Reagan budget director David Stockman thinks is going down. That’s the headline from latest ad from Stockman’s Bubble Finance Trader newsletter service, which was launched fairly […]
Options trading advisory from former Reagan budget director David Stockman, who is looking for “bubble” stocks to bet against by buying put options (maybe other “bubble popping” trades as well, but put options are what has been promoted thus far).
Yes, that’s not my headline — I borrowed it from the ad I was asked to look at, the “special presentation for fast-moving readers” from Agora Financial’s Microcap Millionaires. The other possible headline would have been, also from the ad, “This Tiny Company Could Be The Next Household-Name Mega-Brand.” So you see, that’s not much […]
Today we’ve got a two-fer — two different big publishers are teasing different “liquid biopsy” stocks, and I’m no expert on the technology or the prospects for this diagnostic “trend” that we’ve been hearing more about… so I’ll just sift the clues, identify the companies, and let you chatter about their merits amongst yourselves. The […]
I know I’ve said this before, and sometimes it’s a lie: I’m going to try to keep this one brief. Agora Financial’s FDA Trader service has a new pitch out — which normally might not get that much attention, since everyone is suddenly terrified of biotech stocks after a brutal month or two — but […]
Pain management is a huge market in the medical world, as you’re no doubt aware — and buckets of money are pouring down on the many, many little biotech stocks who are trying to develop new pain medications, or to tweak existing medications to make them safer or less likely to be abused. So it’s […]
Premium priced advisory from Byron King and Agora, largely focused on finding technology investments that started with military funding or have some defense connection, ranging from cybersecurity to biotech.
I always like reading Chris Mayer’s stuff — he often presents at the Value Investing Congress, he seems to be an interesting and low-key guy in person, and the ideas that are pitched by his various newsletters at Agora often catch my eye. They don’t always work out, of course, but every once in a […]
This article was originally published on August 6, 2014 and the ad is circulating again and sending a lot of questions our way. The same stock is being touted and teased, and the original article below has not been updated or revised… the stock teased is up by about 50% since it was first teased, […]
Medical technology is always a prime area for investor excitement — we love the idea of a company that can make things bigger, cheaper, stronger, faster in any field of human endeavor, but somehow the idea of a company doing it in medicine, where we can feel both wealthy and virtuous after investing, is even […]
I’ve got a few thoughts for you on some companies I follow and own, and a little follow-up on last week’s chatter about hedge funds, but first I thought you’d like a quick teaser solution for your Friday File fun… The pitch is for Stephen Petranek’s Breakthrough Technology Alert — there’s been some discussion recently […]
Small cap stock-picking newsletter.
That’s right, the end of obesity. That’s what’s being touted by the new letter that as far as I can tell was just launched moments ago by Agora, which they’re calling FDA Trader and for which they apparently hired away Paul Mampilly from the Palm Beach Letter (OK, they didn’t really “hire him away” — […]
Biotech trading advisory/newsletter.
What is it? “With one click of your mouse you could set yourself up to profit from: The rise of DNA-based personalized medicine; The “holy grail” new computers that could cure cancer; And a revolutionary new mass-produced ’30-minute oil.'”
This is a special bonus solution for the Irregulars, because the company is very, very small and probably quite foolish to trade — if you do buy it and the company doesn’t do well, it will be very hard to sell it quickly. Especially if you’re not willing to take substantial losses. That goes for […]